Floatz logo

Renvatinib

Portal Vein Tumor Thrombus

First Affiliated Hospital of Guangxi Medical UniversityPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Portal Vein Tumor Thrombus cohort.

Asset / SponsorPhaseRating
Sorafenib
First Affiliated Hospital of Zhejiang University
Phase 4BBB
LENVATINIB
First Hospital of China Medical University
Phase 4BBB
WARFARIN
Kafrelsheikh University
Phase 4BB
NADROPARIN
Shanghai Zhongshan Hospital
Phase 4BB
Enoxaparin
Institute of Liver and Biliary Sciences, India
Phase 4BB

View all 27 →

Same molecule, other indications

Renvatinib is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →